LCM Helps Pharma Companies to Retain Revenue Streams, Says CBR Pharma Insights in Its New Topical Report Available at MarketPublishers.com
16 May 2017 • by Natalie Aster
LONDON – At present, the global pharma industry boasts a high level of competition. It is also highly lucrative, and companies invest significant sums of money and amount of time and human resources into maintaining revenue streams of the products they manufacture.
The industry is set to continue combating an extensive array of challenges in the years to come. Some of these issues comprise: a productivity decline, low reimbursement levels, patent cliffs, and more.
The product lifecycle (LCM) management plays a vital role in solving these problems. Cipla, Teva, and Pfizer boast successful LCM strategies.
In-demand research report “Pharmaceutical Lifecycle Management Strategies in 2017” drawn up by CBR Pharma Insights offers a comprehensive discussion of the global pharma market, with a focus on LCM. The study starts with an all-round overview of the worldwide LCM strategies.
It sheds light on commercial strategies, including geographical expansion, customer retention programs, pricing strategies, and more. The report explores regulatory and legal strategies in detail.
The research study canvasses development strategies, too. It comprises valuable case studies and discloses patent expiry dates of best selling pharmaceuticals over the period 2005-2016. The report also contains LCM strategies of pipeline products in 2017.
Reasons to Buy:
- keep abreast of the most successful LCM strategies in the pharma space;
- find out challenges, risk, and potential benefits associated with LCM strategies;
- get access to case studies;
- acquire information pertaining to strategies of products currently being under development.
More insightful studies by CBR Pharma Insights can be found at its page.
Feel free to benefit from the discount scheme by obtaining reports of our partner at a special price.